- Takeda and Arrowhead agree to a partnership on Arrowhead's ARO-AAT, with Takeda getting U.S. co-promotion rights and exclusive ex-US rights.
- Arrowhead is getting $300 million upfront, up to $740 million in future milestone payments, U.S. co-promotion rights, and 20% to 25% royalties on ex-US sales.
- Phase II data suggests ARO-AAT has an impressive impact on AATLD, leading to quick reductions in mutant protein levels and liver enzymes.
- Takeda is paying a fair price for a potential multibillion-dollar blockbuster, while Arrowhead gets a strong commercial partner and more cash to advance its other pipeline candidates.
For further details see:
Takeda Broadens Its Rare Disease Portfolio By Partnering With Arrowhead